![Flow of patients through the OLE study. These numbers refer to status... | Download Scientific Diagram Flow of patients through the OLE study. These numbers refer to status... | Download Scientific Diagram](https://www.researchgate.net/publication/290183533/figure/fig1/AS:567320854659072@1512271240438/Flow-of-patients-through-the-OLE-study-These-numbers-refer-to-status-at-the-time-of-the.png)
Flow of patients through the OLE study. These numbers refer to status... | Download Scientific Diagram
![NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience® (Mazindol ER) in the Treatment of Narcolepsy - Wake Up Narcolepsy NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience® (Mazindol ER) in the Treatment of Narcolepsy - Wake Up Narcolepsy](https://www.wakeupnarcolepsy.org/wp-content/uploads/2022/11/double-blind-study-2.png)
NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience® (Mazindol ER) in the Treatment of Narcolepsy - Wake Up Narcolepsy
![Overall PrEP effectiveness in iPrEx OLE study 50%, but 100% in those taking four or more doses a week | aidsmap Overall PrEP effectiveness in iPrEx OLE study 50%, but 100% in those taking four or more doses a week | aidsmap](https://www.aidsmap.com/sites/default/files/styles/aidsmap_social_default/public/2014-07/overall-prep-effectiveness-in-iprex-ole-study-50-but-100-in-those-taking-four-or-more-doses-a-week.jpg?itok=d-v8Otn6)
Overall PrEP effectiveness in iPrEx OLE study 50%, but 100% in those taking four or more doses a week | aidsmap
![Disposition for all patients entering the open-label extension (OLE)... | Download Scientific Diagram Disposition for all patients entering the open-label extension (OLE)... | Download Scientific Diagram](https://www.researchgate.net/publication/233396586/figure/fig3/AS:289023215063066@1445919912895/Figure2-Disposition-for-all-patients-entering-the-open-label-extension-OLE-study-ITT.png)
Disposition for all patients entering the open-label extension (OLE)... | Download Scientific Diagram
![Figure 2, Study 1434 – Timeline of Patients Feeding Into the OLE from Parent Studies - Clinical Review Report: Dupilumab (Dupixent) - NCBI Bookshelf Figure 2, Study 1434 – Timeline of Patients Feeding Into the OLE from Parent Studies - Clinical Review Report: Dupilumab (Dupixent) - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK565244/bin/cl4f2.jpg)
Figure 2, Study 1434 – Timeline of Patients Feeding Into the OLE from Parent Studies - Clinical Review Report: Dupilumab (Dupixent) - NCBI Bookshelf
![Flow chart showing the study design of the open-label extension phase... | Download Scientific Diagram Flow chart showing the study design of the open-label extension phase... | Download Scientific Diagram](https://www.researchgate.net/publication/337470199/figure/fig2/AS:836912487088133@1576546894872/Flow-chart-showing-the-study-design-of-the-open-label-extension-phase-OLE-of-the.png)
Flow chart showing the study design of the open-label extension phase... | Download Scientific Diagram
![Dapivirine ring OLE study results featured in The Lancet HIV | International Partnership For Microbicides Dapivirine ring OLE study results featured in The Lancet HIV | International Partnership For Microbicides](https://www.ipmglobal.org/sites/default/files/styles/modal_image/public/image/publication/lancet_hiv_ring_ole_issue_feb_2021.png?itok=KzddesJc)
Dapivirine ring OLE study results featured in The Lancet HIV | International Partnership For Microbicides
![Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE) - The Lancet Respiratory Medicine Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE) - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/attachment/2080281341/2071722850/gr1.gif)
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE) - The Lancet Respiratory Medicine
![Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE) | SpringerLink Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40257-022-00683-2/MediaObjects/40257_2022_683_Fig1_HTML.png)
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE) | SpringerLink
![Understanding Clinical Trial Terminology: What is a Long-Term Extension or Open-Label Extension Study? - Concert Pharmaceuticals Understanding Clinical Trial Terminology: What is a Long-Term Extension or Open-Label Extension Study? - Concert Pharmaceuticals](https://www.concertpharma.com/wp-content/uploads/2020/08/shutterstock_1165019548-scaled-e1597922554371.jpg)
Understanding Clinical Trial Terminology: What is a Long-Term Extension or Open-Label Extension Study? - Concert Pharmaceuticals
![Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies | tctmd.com Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies | tctmd.com](https://d18mqtxkrsjgmh.cloudfront.net/public/2022-08/ODonoghue_FOURIER-OLE.png)